Cargando…

Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews

AIM: The current overview on published systematic reviews (SRs) and meta-analysis (MAs) aimed to systematically gather, evaluate, and synthesize solid evidence for using fecal microbiota transplantation (FMT) to treat ulcerative colitis (UC). METHODS: Relevant articles published before January 2023...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Haixia, Li, Jing, Yuan, Jiaxin, Huang, Jinke, Xu, Youqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685500/
https://www.ncbi.nlm.nih.gov/pubmed/38030980
http://dx.doi.org/10.1186/s12866-023-03107-1
_version_ 1785151645564272640
author Liu, Haixia
Li, Jing
Yuan, Jiaxin
Huang, Jinke
Xu, Youqi
author_facet Liu, Haixia
Li, Jing
Yuan, Jiaxin
Huang, Jinke
Xu, Youqi
author_sort Liu, Haixia
collection PubMed
description AIM: The current overview on published systematic reviews (SRs) and meta-analysis (MAs) aimed to systematically gather, evaluate, and synthesize solid evidence for using fecal microbiota transplantation (FMT) to treat ulcerative colitis (UC). METHODS: Relevant articles published before January 2023 were collected from Web of Science, Embase, PubMed, and Cochrane Library. Two authors used Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) tool, PRISMA checklists, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system were applied by two authors to independently evaluate the methodological quality, reporting quality, and evidence quality, respectively. Re-meta-analysis on the primary RCTs was conducted after excluding overlapping randomized controlled trials (RCTs). RESULTS: Six SRs/MAs involving 12 primary RCTs and 544 participants were included. According to the AMSTAR-2 tool and PRISMA checklist, methodological quality and reporting quality of the included studies was overall satisfactory. The evidence quality of a great majority of outcomes was rated as moderate to high according to the GRADE system. Compared to placebo, the re-meta-analysis found a great advantage of use FMT in inducing combined clinical and endoscopic remission (OR 3.83 [2.31, 6.34]), clinical remission (3.31 [2.09, 5.25]), endoscopic remission (OR 3.75 [2.20, 6.39]), clinical response (OR 2.56 [1.64, 4.00]), and endoscopic response (OR 2.18 [1.12, 4.26]). Pooled data showed no significant difference in serious adverse events between patients receiving FMT and those receiving placebo (OR 1.53 [0.74, 3.19]). Evidence quality of the outcomes derived from re-meta-analysis was significantly higher after overcoming the limitations of previous SRs/MAs. CONCLUSION: In conclusion, moderate- to high-quality evidence supported a promising use of FMT to safely induce remission in UC. However, further trials with larger sample size are still required to comprehensively analyze the delivery route, total dosage, frequency, and donor selection in FMT.
format Online
Article
Text
id pubmed-10685500
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106855002023-11-30 Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews Liu, Haixia Li, Jing Yuan, Jiaxin Huang, Jinke Xu, Youqi BMC Microbiol Research AIM: The current overview on published systematic reviews (SRs) and meta-analysis (MAs) aimed to systematically gather, evaluate, and synthesize solid evidence for using fecal microbiota transplantation (FMT) to treat ulcerative colitis (UC). METHODS: Relevant articles published before January 2023 were collected from Web of Science, Embase, PubMed, and Cochrane Library. Two authors used Assessment of Multiple Systematic Reviews 2 (AMSTAR-2) tool, PRISMA checklists, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system were applied by two authors to independently evaluate the methodological quality, reporting quality, and evidence quality, respectively. Re-meta-analysis on the primary RCTs was conducted after excluding overlapping randomized controlled trials (RCTs). RESULTS: Six SRs/MAs involving 12 primary RCTs and 544 participants were included. According to the AMSTAR-2 tool and PRISMA checklist, methodological quality and reporting quality of the included studies was overall satisfactory. The evidence quality of a great majority of outcomes was rated as moderate to high according to the GRADE system. Compared to placebo, the re-meta-analysis found a great advantage of use FMT in inducing combined clinical and endoscopic remission (OR 3.83 [2.31, 6.34]), clinical remission (3.31 [2.09, 5.25]), endoscopic remission (OR 3.75 [2.20, 6.39]), clinical response (OR 2.56 [1.64, 4.00]), and endoscopic response (OR 2.18 [1.12, 4.26]). Pooled data showed no significant difference in serious adverse events between patients receiving FMT and those receiving placebo (OR 1.53 [0.74, 3.19]). Evidence quality of the outcomes derived from re-meta-analysis was significantly higher after overcoming the limitations of previous SRs/MAs. CONCLUSION: In conclusion, moderate- to high-quality evidence supported a promising use of FMT to safely induce remission in UC. However, further trials with larger sample size are still required to comprehensively analyze the delivery route, total dosage, frequency, and donor selection in FMT. BioMed Central 2023-11-29 /pmc/articles/PMC10685500/ /pubmed/38030980 http://dx.doi.org/10.1186/s12866-023-03107-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Haixia
Li, Jing
Yuan, Jiaxin
Huang, Jinke
Xu, Youqi
Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews
title Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews
title_full Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews
title_fullStr Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews
title_full_unstemmed Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews
title_short Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews
title_sort fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685500/
https://www.ncbi.nlm.nih.gov/pubmed/38030980
http://dx.doi.org/10.1186/s12866-023-03107-1
work_keys_str_mv AT liuhaixia fecalmicrobiotatransplantationasatherapyfortreatingulcerativecolitisanoverviewofsystematicreviews
AT lijing fecalmicrobiotatransplantationasatherapyfortreatingulcerativecolitisanoverviewofsystematicreviews
AT yuanjiaxin fecalmicrobiotatransplantationasatherapyfortreatingulcerativecolitisanoverviewofsystematicreviews
AT huangjinke fecalmicrobiotatransplantationasatherapyfortreatingulcerativecolitisanoverviewofsystematicreviews
AT xuyouqi fecalmicrobiotatransplantationasatherapyfortreatingulcerativecolitisanoverviewofsystematicreviews